The University of Chicago Header Logo

Connection

Walter M. Stadler to Proto-Oncogene Proteins c-met

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Proto-Oncogene Proteins c-met.
Walter M. Stadler
Connection Strength
0.139
Proto-Oncogene Proteins c-met
  1. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.
    View in: PubMed
    Score: 0.139
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.